Skip to main content

Table 3 HCPs knowledge toward indications and adverse effects of FQs

From: Evaluation of healthcare professionals' understanding of fluoroquinolones' safety profile, usage, and boxed warnings in Pakistan

 

Yes

No

Not sure

Mean ± SD

N

%

N

%

N

%

 

Indications

Bacterial eye infection

53

28.5

123

66.1

10

5.4

0.39 ± 0.59

Corneal ulcer

78

41.9

92

49.5

16

8.6

0.59 ± 0.64

Otitis externa

93

50.0

84

45.2

9

4.8

0.60 ± 0.58

Respiratory tract infections

114

61.3

57

30.6

15

8.1

0.77 ± 0.58

Urinary tract infections

115

61.8

38

20.4

33

17.7

0.97 ± 0.61

Skin & soft tissue infections

84

45.2

61

32.8

41

22

0.89 ± 0.73

Gonorrhea

58

31.2

83

44.6

45

24.2

0.80 ± 0.80

Surgical prophylaxis

56

30.1

91

48.9

39

21

0.72 ± 0.79

Anthrax

48

25.8

86

46.2

52

28

0.82 ± 0.84

Meningococcal meningitis

82

44.1

68

36.6

36

19.4

0.83 ± 0.73

Fistulating Crohn’s disease

66

35.5

91

48.9

29

15.6

0.67 ± 0.73

Typhoid fever

108

58.1

62

33.3

16

8.6

0.75 ± 0.60

Average knowledge score for indications domain (out of 12)

5.13 ± 1.59

Adverse effects

       

Nauseas or vomiting

59

31.7

106

57

21

11.3

0.54 ± 0.69

Diarrhea

93

50

84

45.2

9

4.8

0.60 ± 0.58

Arthropathy

100

53.8

79

42.5

7

3.8

0.61 ± 0.56

Loss of appetite

88

47.3

75

40.3

23

12.4

0.72 ± 0.67

Musculoskeletal pain

82

44.1

78

41.9

26

14

0.72 ± 0.69

Renal impairment

88

47.3

77

41.4

21

11.3

0.70 ± 0.66

Hepatic impairment

83

44.6

77

41.4

26

14

0.73 ± 0.69

Headache

75

40.3

86

46.2

25

13.4

0.67 ± 0.70

Dizziness

59

31.7

96

51.6

31

16.7

0.65 ± 0.75

Seizures

61

32.8

86

46.2

39

21

0.75 ± 0.78

Dyspnea

81

43.5

83

44.6

22

11.8

0.67 ± 0.68

Trouble sleeping

82

44.1

69

37.1

35

18.8

0.82 ± 0.72

Altered smell sensation

73

39.2

73

39.2

40

21.5

0.82 ± 0.76

Asthenia

69

37.1

95

51.1

22

11.8

0.61 ± 0.69

Sensation abnormalities (peripheral neuropathy)

82

44.1

80

43

24

12.9

0.70 ± 0.69

Clostridium difficile infections

58

31.2

117

62.9

11

5.9

0.43 ± 0.60

Cardiovascular problems

88

47.3

86

46.2

12

6.5

0.60 ± 0.60

Photosensitivity or skin reactions

112

60.2

61

32.8

13

7

0.74 ± 0.58

Average knowledge score for adverse effects domain (out of 18)

7.70 ± 2.61

Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us